Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 84, Issue 2, 2013, Pages 335-344

  Ivanova, Vera ^a   Garbuzenko, Olga B ^a   Reuhl, Kenneth R ^a,b   Reimer, David C ^a   Pozharov, Vitaly P ^a   Minko, Tamara ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Fibrosis; Gene and protein expression; Hydroxyproline; Liposomes; Prostaglandin E2; Pulmonary delivery

Indexed keywords

BLEOMYCIN; HYDROXYPROLINE; LIPOSOME; MESSENGER RNA; PROSTAGLANDIN E2;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY DISTRIBUTION; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY; LIPOSOMAL DELIVERY; LIVER; LUNG; LUNG ALVEOLUS CELL; LUNG FIBROSIS; MORTALITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPLEEN; SURVIVAL; TISSUE DISTRIBUTION;

ADMINISTRATION, INTRAVENOUS; ANIMALS; BLEOMYCIN; BODY WEIGHT; DINOPROSTONE; DISEASE MODELS, ANIMAL; HYDROXYPROLINE; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOHISTOCHEMISTRY; KIDNEY; LIPOSOMES; LIVER; LUNG; MICE; RNA, MESSENGER; SPLEEN; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84878291329     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.11.023     Document Type: Article

References (57)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001, Am. J. Respir. Crit. Care Med. 165 (2002) 277-304.
2. M. Gharaee-Kermani, M.R. Gyetko, B. Hu, and S.H. Phan New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy Pharm. Res. 24 2007 819 841
3. P.J. Sime, and K.M. O'Reilly Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment Clin. Immunol. 99 2001 308 319
4. S.K. Frankel, and M.I. Schwarz Update in idiopathic pulmonary fibrosis Curr. Opin. Pulm. Med. 15 2009 463 469
5. T.J. Williams, and J.W. Wilson Challenges in pulmonary fibrosis: 7-Novel therapies and lung transplantation Thorax 63 2008 277 284
6. C. Vancheri, C. Mastruzzo, M.A. Sortino, and N. Crimi The lung as a privileged site for the beneficial actions of PGE2 Trends Immunol. 25 2004 40 46
7. P.D. Bozyk, and B.B. Moore Prostaglandin E2 and the pathogenesis of pulmonary fibrosis Am. J. Respir. Cell Mol. Biol. 45 2011 445 452
8. S.K. Huang, S.H. Wettlaufer, J. Chung, and M. Peters-Golden Prostaglandin E2 inhibits specific lung fibroblast functions via selective actions of PKA and Epac-1 Am. J. Respir. Cell Mol. Biol. 39 2008 482 489
9. S.K. Huang, S.H. Wettlaufer, C.M. Hogaboam, K.R. Flaherty, F.J. Martinez, J.L. Myers, T.V. Colby, W.D. Travis, G.B. Toews, and M. Peters-Golden Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia Am. J. Respir. Crit. Care Med. 177 2008 66 74
10. M. Ghosh, A. Stewart, D.E. Tucker, J.V. Bonventre, R.C. Murphy, and C.C. Leslie Role of cytosolic phospholipase A(2) in prostaglandin E(2) production by lung fibroblasts Am. J. Respir. Cell Mol. Biol. 30 2004 91 100
11. M. Failla, T. Genovese, E. Mazzon, M. Fruciano, E. Fagone, E. Gili, A. Barera, C. La Rosa, E. Conte, N. Crimi, S. Cuzzocrea, and C. Vancheri 16,16-Dimethyl prostaglandin E2 efficacy on prevention and protection from bleomycin-induced lung injury and fibrosis Am. J. Respir. Cell Mol. Biol. 41 2009 50 58
12. T. Minko, A. Stefanov, and V. Pozharov Selected contribution: lung hypoxia: antioxidant and antiapoptotic effects of liposomal alpha-tocopherol J. Appl. Physiol. 93 2002 1550 1560 (discussion 1549)
13. O.B. Garbuzenko, M. Saad, S. Betigeri, M. Zhang, A.A. Vetcher, V.A. Soldatenkov, D.C. Reimer, V.P. Pozharov, and T. Minko Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug Pharm. Res. 26 2009 382 394
14. O.B. Garbuzenko, M. Saad, V.P. Pozharov, K.R. Reuhl, G. Mainelis, and T. Minko Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance Proc. Natl. Acad. Sci. USA 107 2010 10737 10742
15. O. Taratula, O.B. Garbuzenko, A.M. Chen, and T. Minko Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA J. Drug Target. 19 2011 900 914
16. B.B. Moore, and C.M. Hogaboam Murine models of pulmonary fibrosis Am. J. Physiol. Lung Cell Mol. Physiol. 294 2008 L152 L160
17. A.L. Babin, C. Cannet, C. Gerard, P. Saint-Mezard, C.P. Page, H. Sparrer, T. Matsuguchi, and N. Beckmann Bleomycin-induced lung injury in mice investigated by MRI: model assessment for target analysis Magn. Reson. Med. 67 2012 499 509
18. E.R. Banerjee, and W.R. Henderson Jr. Characterization of lung stem cell niches in a mouse model of bleomycin-induced fibrosis Stem Cell Res. Ther. 3 2012 21
19. L.O. Prata, F.M. Oliveira, T.M. Ribeiro, P.W. Almeida, J.A. Cardoso, G. Rodrigues-Machado Mda, and M.V. Caliari Exercise attenuates pulmonary injury in mice with bleomycin-induced pulmonary fibrosis Exp. Biol. Med. (Maywood) 237 2012 873 883
20. K. Tanaka, A. Shirai, Y. Ito, T. Namba, K. Tahara, N. Yamakawa, and T. Mizushima Expression of 150-kDa oxygen-regulated protein (ORP150) stimulates bleomycin-induced pulmonary fibrosis and dysfunction in mice Biochem. Biophys. Res. Commun. 425 2012 818 824
21. S. Betigeri, M. Zhang, O. Garbuzenko, and T. Minko Non-viral systemic delivery of siRNA or antisense oligonucleotides targeted to Jun N-terminal kinase 1 prevents cellular hypoxic damage Drug Deliv. Transl. Res. 1 2011 13 24
22. M. Saad, O.B. Garbuzenko, and T. Minko Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer Nanomedicine (London) 3 2008 761 776
23. Y. Wang, M. Saad, R.I. Pakunlu, J.J. Khandare, O.B. Garbuzenko, A.A. Vetcher, V.A. Soldatenkov, V.P. Pozharov, and T. Minko Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor Clin. Cancer Res. 14 2008 3607 3616
24. A. Schroeder, Y. Avnir, S. Weisman, Y. Najajreh, A. Gabizon, Y. Talmon, J. Kost, and Y. Barenholz Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility Langmuir 23 2007 4019 4025
25. G. Lu, J. Liao, G. Yang, K.R. Reuhl, X. Hao, and C.S. Yang Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine Cancer Res. 66 2006 11494 11501
26. T. Minko, R.I. Pakunlu, Y. Wang, J.J. Khandare, and M. Saad New generation of liposomal drugs for cancer Anticancer Agents Med. Chem. 6 2006 537 552
27. R.I. Pakunlu, Y. Wang, M. Saad, J.J. Khandare, V. Starovoytov, and T. Minko In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug J. Control. Release 114 2006 153 162
28. F. Huaux, M. Gharaee-Kermani, T. Liu, V. Morel, B. McGarry, M. Ullenbruch, S.L. Kunkel, J. Wang, Z. Xing, and S.H. Phan Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis Am. J. Pathol. 167 2005 1485 1496
29. M. Awad, V. Pravica, C. Perrey, A. El Gamel, N. Yonan, P.J. Sinnott, and I.V. Hutchinson CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis Hum. Immunol. 60 1999 343 346
30. C.G. Lee, R.J. Homer, L. Cohn, H. Link, S. Jung, J.E. Craft, B.S. Graham, T.R. Johnson, and J.A. Elias Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways J. Biol. Chem. 277 2002 35466 35474
31. M.R. Blackburn, C.G. Lee, H.W. Young, Z. Zhu, J.L. Chunn, M.J. Kang, S.K. Banerjee, and J.A. Elias Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway J. Clin. Invest. 112 2003 332 344
32. S. Fichtner-Feigl, W. Strober, K. Kawakami, R.K. Puri, and A. Kitani IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis Nat. Med. 12 2006 99 106
33. D.A. Kuperman, X. Huang, L.L. Koth, G.H. Chang, G.M. Dolganov, Z. Zhu, J.A. Elias, D. Sheppard, and D.J. Erle Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma Nat. Med. 8 2002 885 889
34. Z. Zhu, R.J. Homer, Z. Wang, Q. Chen, G.P. Geba, J. Wang, Y. Zhang, and J.A. Elias Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production J. Clin. Invest. 103 1999 779 788
35. Y. Fukuda, M. Ishizaki, S. Kudoh, M. Kitaichi, and N. Yamanaka Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases Lab. Invest. 78 1998 687 698
36. M. Selman, T.E. King, and A. Pardo Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy Ann. Internal Med. 134 2001 136 151
37. T. Yaguchi, Y. Fukuda, M. Ishizaki, and N. Yamanaka Immunohistochemical and gelatin zymography studies for matrix metalloproteinases in bleomycin-induced pulmonary fibrosis Pathol. Int. 48 1998 954 963
38. K. Ask, G.E. Martin, M. Kolb, and J. Gauldie Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls Proc. Am. Thorac. Soc. 3 2006 389 393
39. Z. Borok Role for alpha3 integrin in EMT and pulmonary fibrosis J. Clin. Invest. 119 2009 7 10
40. H. Liu, Y. Peng, F. Liu, J. Li, X. Chen, Y. Liu, and H. Zhang A selective cyclooxygenase-2 inhibitor decreases transforming growth factor-beta1 synthesis and matrix production in human peritoneal mesothelial cells Cell Biol. Int. 31 2007 508 515
41. E.M. Zeisberg, O. Tarnavski, M. Zeisberg, A.L. Dorfman, J.R. McMullen, E. Gustafsson, A. Chandraker, X. Yuan, W.T. Pu, A.B. Roberts, E.G. Neilson, M.H. Sayegh, S. Izumo, and R. Kalluri Endothelial-to-mesenchymal transition contributes to cardiac fibrosis Nat. Med. 13 2007 952 961
42. N. Oikonomou, V. Harokopos, J. Zalevsky, C. Valavanis, A. Kotanidou, D.E. Szymkowski, G. Kollias, and V. Aidinis Soluble TNF mediates the transition from pulmonary inflammation to fibrosis PLoS One 1 2006 e108
43. T. Suda, T. Takahashi, P. Golstein, and S. Nagata Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family Cell 75 1993 1169 1178
44. K. Zhang, M. Gharaee-Kermani, B. McGarry, D. Remick, and S.H. Phan TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis J. Immunol. 158 1997 954 959
45. S.A. Antoniu Targeting the angiotensin pathway in idiopathic pulmonary fibrosis Expert Opin. Ther. Targets 12 2008 1587 1590
46. T. Matsuse, Y. Fukuchi, Y. Eto, H. Matsui, T. Hosoi, T. Oka, E. Ohga, T. Nagase, and H. Orimo Expression of immunoreactive and bioactive activin A protein in adult murine lung after bleomycin treatment Am. J. Respir. Cell Mol. Biol. 13 1995 17 24
47. D. Sheppard The role of integrins in pulmonary fibrosis Eur. Respir. Rev. 17 2008 157 162
48. B.L. Copple, S. Kaska, and C. Wentling Hypoxia-inducible factor activation in myeloid cells contributes to the development of liver fibrosis in cholestatic mice J. Pharmacol. Exp. Ther. 2012
49. V.H. Haase Pathophysiological consequences of HIF activation: HIF as a modulator of fibrosis Ann. N. Y. Acad. Sci. 1177 2009 57 65
50. N. Halberg, T. Khan, M.E. Trujillo, I. Wernstedt-Asterholm, A.D. Attie, S. Sherwani, Z.V. Wang, S. Landskroner-Eiger, S. Dineen, U.J. Magalang, R.A. Brekken, and P.E. Scherer Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue Mol. Cell Biol. 29 2009 4467 4483
51. K. Kimura, M. Iwano, D.F. Higgins, Y. Yamaguchi, K. Nakatani, K. Harada, A. Kubo, Y. Akai, E.B. Rankin, E.G. Neilson, V.H. Haase, and Y. Saito Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis Am. J. Physiol. Renal Physiol. 295 2008 F1023 F1029
52. J.O. Moon, T.P. Welch, F.J. Gonzalez, and B.L. Copple Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice Am. J. Physiol. Gastrointest. Liver Physiol. 296 2009 G582 G592
53. F. Theilig, A.K. Enke, B. Scolari, D. Polzin, S. Bachmann, and R. Koesters Tubular deficiency of von Hippel-Lindau attenuates renal disease progression in anti-GBM glomerulonephritis Am. J. Pathol. 179 2011 2177 2188
54. V. Tiriveedhi, A.E. Gelman, and T. Mohanakumar HIF-1alpha signaling by airway epithelial cell K-alpha1-tubulin: role in fibrosis and chronic rejection of human lung allografts Cell Immunol. 273 2012 59 66
55. M. Ueno, T. Maeno, M. Nomura, K. Aoyagi-Ikeda, H. Matsui, K. Hara, T. Tanaka, T. Iso, T. Suga, and M. Kurabayashi Hypoxia-inducible factor-1alpha mediates TGF-beta-induced PAI-1 production in alveolar macrophages in pulmonary fibrosis Am. J. Physiol. Lung Cell Mol. Physiol. 300 2011 L740 L752
56. Q. Zhou, A. Pardo, M. Konigshoff, O. Eickelberg, G.R. Budinger, K. Thavarajah, C.J. Gottardi, J. Jones, J. Varga, M. Selman, J.I. Sznajder, J.U. Raj, and G. Zhou Role of von Hippel-Lindau protein in fibroblast proliferation and fibrosis Faseb J. 25 2011 3032 3044
57. M. Molina-Molina, A. Serrano-Mollar, O. Bulbena, L. Fernandez-Zabalegui, D. Closa, A. Marin-Arguedas, A. Torrego, J. Mullol, C. Picado, and A. Xaubet Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis Thorax 61 2006 604 610